Skip to main content

Industry News

  • AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion

    AstraZenecas proposed acquisition of Alexion Pharmaceuticals, Inc.has achieved an important step towards completion by having cleared the European Commission review.

    The clearance follows competition clearances in the United States, Japan and other countries globally, with a complete list available on astrazeneca.com. Regulatory clearance in the UK is pending and remains a requirement to complete the deal.

  • Carbamazepine, Ranitidine and Ibuprofen cost hikes by 50 percent
    Carbamazepine, Ranitidine and Ibuprofen cost hikes by 50 percent

    National Pharmaceutical Pricing Authority (NPPA) allows price hikes of essential medicines like Carbamazepine, Ranitidine and ibuprofen by 50 percent. They have included 9 strengths of these medicines and allows manufacturers to increase pricing after being advised by the Standing Committee on Affordable Medicines and Health Products (SCAMHP), Niti Aayog, Government of India.

  • AI based start-up Niramai raised funding from CDC group
    AI based start-up Niramai raised funding from CDC group

    Niramai Health Analytix, a Deeptech health startup raised research funding from impact investor CDC for NIRAMAI FeverTest, which was launched last year.

    With leveraging of computer vision and AI to analyze and monitor crowd compliance to COVID-19 guidelines, NIRAMAI FeverTest’s smart software enables screening for COVID-19 symptoms in public places.

  • Sandoz to launch ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer in Europe
    Sandoz to launch ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer in Europe

    Sandoz announced the launch of generic oncology treatment Pemetrexed in 11 countries across Europe, including Germany, Switzerland, Netherlands, and Spain.

    Pemetrexed, as a monotherapy or in combination with cisplatin, is indicated for first-line, second-line and maintenance treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology, and for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

  • Zydus and Bayer announce continuity of their successful Joint Venture
    Zydus and Bayer announce continuity of their successful Joint Venture

    Bayer Pte Ltd and Cadila Healthcare Limited announced the extension of their Joint Venture by three years from June 2021. The companies first entered into an agreement on January 28, 2011 to set up the Joint Venture - Bayer Zydus Pharma Private Limited for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.

  • Empagliflozin approved in Europe for the treatment of heart failure
    Empagliflozin approved in Europe for the treatment of heart failure

    Todays approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and more time with their families.

  • Medtronic launches smallest pacemaker with Atrioventricular synchrony
    Medtronic launches smallest pacemaker with Atrioventricular synchrony

    India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of Micra AV - a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to atrioventricular (AV) block patients via a minimally invasive approach. The device is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart

  • Glenmark launches bioequivalent of Tiotropium Bromide for treatment of COPD
    Glenmark launches bioequivalent of Tiotropium Bromide for treatment of COPD

    Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

  • NATCO receives approval for Carfilzomib Vials ANDA in the US market
    NATCO receives approval for Carfilzomib Vials ANDA in the US market

    Natco Pharma Limited is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received approval for its Abbreviated New Drug Application (ANDA) for Carfilzomib Vials ANDA (generic for KYPROLIS), from the U.S. Food and Drug Administration (USFDA).

  • Indian Pharmaceutical industry affected by counterfeiting challenges
    Indian Pharmaceutical industry affected by counterfeiting challenges

    Indian Pharmaceutical industry amongst five sectors affected by counterfeiting Incidents reported by Authentication Solution Providers Association, ASPA. There was a sharp spike in crimes related to illicit liquor, smuggling of tobacco products and pharmaceutical products especially PPE kits and sanitizers, etc during the COVID-19 lockdown.

Subscribe to Industry News